Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease. A pilot study

Inflammatory Bowel Diseases

Volumn 11, Issue 1, 2005, Pages 8-15

  González Lama, Yago ^a   Abreu, Luis ^a   Vera, Maria Isabel ^a   Pastrana, Miguel ^a   Tabernero, Susana ^b   Revilla, Juan ^a   Gómez Durán, Juan ^a   Escartin, Pedro ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Crohn's disease; Fistulas; Nephroticity; Oral tacrolimus

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AMINOTRANSFERASE; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CIPROFLOXACIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METRONIDAZOLE; PREDNISONE; STEROID; TACROLIMUS; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; ALOPECIA; ANAPHYLAXIS; ANUS FISTULA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DIABETES MELLITUS; DIARRHEA; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCUTANEOUS FISTULA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; INSOMNIA; INTESTINE FISTULA; LIVER DYSFUNCTION; LIVER TOXICITY; LONG TERM CARE; MAINTENANCE THERAPY; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OPPORTUNISTIC INFECTION; PARESTHESIA; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTOVAGINAL FISTULA; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREMOR; VOMITING; AGED; DIGESTIVE SYSTEM FISTULA; DRUG ADMINISTRATION; DRUG RESISTANCE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DIGESTIVE SYSTEM FISTULA; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 13944281772     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200501000-00002     Document Type: Article

References (42)

1. Egan LJ, Sandborn WJ. Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol. 1998;93:442-448.
2. Santos JV, Bauder JA, Casellas FJ, et al. Intravenous cyclosporine for steroid - refractory attacks of Crohn's disease: short and long term results. J Clin Gastroenterol. 1995;20:207-210.
3. Keating S, Morrison C, Buckley M, et al. The use of cyclosporine in the management of acute exacerbations of inflammatory bowel disease. Gastroenterology. 1995;108:A846.
4. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporine A. Am J Gastroenterol. 1993;88: 646-649.
5. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci. 1994;39:374-380.
6. Oneill J, Pathmakanthan S, Goh J, et al. Cyclosporine A induces remission in fistulous Crohn's disease but relapse occurs upon cessation of treatment. Gastroenterology. 1997;112:A1056.
7. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporine in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999;94:1587-1592.
8. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. 1994;331:1110-1115.
9. Matsuhashi N, Nakajima A, Watanabe K, et al. Tacrolimus (FK 506), a novel imosuppressive drug for inflammatory bowel disease? J Gastroenterol. 2000;35:655-657.
10. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing's disease. Am J Gastroenterol. 1997;5:876-879.
11. Fellerman K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol. 1998;93:1860-1866.
12. Matsuhashi N, Nakajima A, Watanabe K, et al. Tacrolimus in corticosteroid-resistant ulcerative colitis. J Gastroenterol. 2000;35:635-640.
13. Ierardi E, Principi M, Francavilla R, et al. Long-term tacrolimus: a promising approach for Crohn's disease. Transplant Proc. 2001;33:2107-2109.
14. Fellermann K, Herrlinger KR, Witthoeft T, et al. Tacrolimus: a new immunosuppressant for steroid refractory inflammatory bowel disease. Transplant Proc. 2001;33:2247-2248.
15. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK 506). Inflamm Bowel Dis. 2002; 8:317-324.
16. Lowry PW, Waever AL, Tremaine WJ, et al. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis. 1999;5:239-245.
17. Ierardi E, Principi M, Rendina M, et al. Oral tacrolimus (FK506) in Crohn's disease complicated by fistulae of the perineum. J Clin Gastroenterol. 2000;39:200-202.
18. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterol. 2003;125:380-388.
19. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
20. Schreiber S, Campieri M, Colomberi JF, et al. Use of anti-tamour necrosis factor agents in inflammatory bowel disease: European guidelines for 2001-2003. Int J Colorectal Dis. 2001;16:1-11.
21. Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs. 2000;59:363-371.
22. Jusko WJ, Thomsom AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK506). Ther Drug Monit. 1995;17:606-614.
23. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. J Clin Gastroenterol. 1995;20:27-32.
24. Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol. 2003;98:332-339.
25. Lang KA, Peppercorn MA. Medical therapy for Crohn's disease. In: Kirsner JB, ed. Inflammatory Bowel Disease. 5th ed. Philadelphia: Saunders; 2000:569-571.
26. Befeler AS, Lissoos TW, Schiano TD, et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation. 1998;65:393-396.
27. Kornbluth A, Present DH, Lichtiger S, et al. Cyclosporin for severe ulcerative colitis: a users guide. Am J Gastroenterol. 1997;92:1424-1428.
28. Ierardi E, Principi M, Francavilla R, et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther. 2001;15:371-377.
29. Present DH. Crohn's fistula: current concepts in management. Gastroenterology. 2003;124:1629-1635.
30. Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis. 1995;1:48-63.
31. Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease: the Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med. 1994;330:1846-1851.
32. Goto T. Discovery, immunopharmacology and rationale for the development of tacrolimus: a novel immunosuppressant of microbial origin. Transplant Proc. 1993;25:502-507.
33. Dumont FJ, Staruch MJ, Koprak SL, et al. The immunosuppressive and toxic effects of FK506 are mechanistically related: pharmacology of a novel antagonist of FK506 and rapamycin. J Exp Med. 1992;176:751-760.
34. Spencer CM, Goa KL, Gillis JC. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs. 1997;54:925-975.
35. Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs. 2000;59:333-334.
36. Abu-Elmagd K, Jegasothy BV, Ackerman CE, et al. Efficacy of FK506 in the treatment of recalcitrant pyoderma gangrenosum. Transplant Proc. 1991;23:3328-3329.
37. Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus (FK506) treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol. 1995;90:455-459.
38. Jain AB, Venkataramanan R, Cadoff E, et al. Effect of hepatic dysfunction and T tube camping on FK506 pharmacokinetics and trough concentrations. Transplant Proc. 1990;22(suppl 1):57-59.
39. Jain AB, Venkataramanan R, Lever J, et al. FK506 in small bowel transplant: pharmacokinetics and dosing. Transplant Proc. 1994;26:1609-1610.
40. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine and methotrexate. Am J Gastroenterol. 1996;91:423-433.
41. Rankin GB, Watts HD, Melnik CS, et al. National cooperative Crohn's disease study: extraintestinal manifestations and perianal complications. Gastroenterology. 1979;77:914-920.
42. Gonzalez-Lama Y, Abreu L, Vera MI, et al. Long term oral tacrolimus in refractoy to Infliximab fistulizing Crohn's disease: comments from the Spanish experience. Gastroenterology. 2004;126:942-943.